OncoTherapy Science, Inc.
4564.T · JPX
3/31/2025 | 3/31/2024 | 3/31/2023 | 3/31/2022 | |
|---|---|---|---|---|
| Revenue | ¥750,048 | ¥610,118 | ¥1,134,903 | ¥1,153,663 |
| % Growth | 22.9% | -46.2% | -1.6% | – |
| Cost of Goods Sold | ¥762,804 | ¥787,836 | ¥1,093,218 | ¥1,039,751 |
| Gross Profit | -¥12,756 | -¥177,718 | ¥41,685 | ¥113,912 |
| % Margin | -1.7% | -29.1% | 3.7% | 9.9% |
| R&D Expenses | ¥491,113 | ¥678,051 | ¥716,463 | ¥1,730,270 |
| G&A Expenses | ¥294,067 | ¥265,030 | ¥431,637 | ¥436,279 |
| SG&A Expenses | ¥294,067 | ¥265,030 | ¥431,637 | ¥436,279 |
| Sales & Mktg Exp. | ¥0 | ¥0 | ¥0 | ¥0 |
| Other Operating Expenses | ¥0 | ¥0 | ¥0 | ¥0 |
| Operating Expenses | ¥785,180 | ¥943,081 | ¥1,148,100 | ¥2,166,549 |
| Operating Income | -¥797,936 | -¥1,120,799 | -¥1,106,415 | -¥2,052,637 |
| % Margin | -106.4% | -183.7% | -97.5% | -177.9% |
| Other Income/Exp. Net | -¥15,189 | -¥164,914 | -¥10,005 | -¥517,669 |
| Pre-Tax Income | -¥813,125 | -¥1,285,713 | -¥1,116,420 | -¥2,570,306 |
| Tax Expense | ¥2,160 | ¥2,425 | ¥2,223 | ¥1,234 |
| Net Income | -¥815,285 | -¥1,288,138 | -¥1,118,644 | -¥2,571,541 |
| % Margin | -108.7% | -211.1% | -98.6% | -222.9% |
| EPS | -3.12 | -6.05 | -5.81 | -13.72 |
| % Growth | 48.4% | -4.1% | 57.7% | – |
| EPS Diluted | -3.12 | -6.05 | -5.81 | -13.72 |
| Weighted Avg Shares Out | 261,144 | 212,783 | 192,644 | 187,466 |
| Weighted Avg Shares Out Dil | 261,144 | 212,783 | 192,644 | 187,466 |
| Supplemental Information | – | – | – | – |
| Interest Income | ¥751 | ¥0 | ¥218 | ¥146 |
| Interest Expense | ¥1,201 | ¥218 | ¥0 | ¥0 |
| Depreciation & Amortization | ¥797,000 | ¥2 | ¥16,000 | ¥16,540 |
| EBITDA | -¥811,924 | -¥1,285,493 | -¥1,091,000 | -¥2,037,000 |
| % Margin | -108.2% | -210.7% | -96.1% | -176.6% |